Keyphrases
Dasatinib
100%
Chronic Myeloid Leukemia
100%
Newly Diagnosed
100%
Frontline Therapy
100%
CML-CP
66%
Molecular Response
50%
Cumulative Rates
33%
Pleural Effusion
33%
Log Reduction
33%
Overall Survival Rate
16%
Blastic Phase
16%
Myelosuppression
16%
Daily Dose
16%
Dose Reduction
16%
Effective Dose
16%
BCR-ABL Inhibitors
16%
Accelerated Phase
16%
Sufficient Follow-up
16%
Event-free Survival
16%
Complete Cytogenetic Response
16%
Response Criteria
16%
Major Molecular Response
16%
Cytogenetic Response
16%
BCR-ABL1 Transcript Levels
16%
Safe Dose
16%
Treatment Interruption
16%
Medicine and Dentistry
Low Drug Dose
100%
Dasatinib
100%
Myeloid Leukemia
100%
Chronic Myelogenous Leukemia
66%
Pleura Effusion
33%
Diseases
16%
Side Effect
16%
Overall Survival
16%
Survival Rate
16%
Drug Dose Reduction
16%
Bone Marrow Suppression
16%
Event Free Survival
16%
Bcr-Abl Tyrosine-Kinase Inhibitor
16%
Treatment Interruption
16%
Pharmacology, Toxicology and Pharmaceutical Science
Dasatinib
100%
Myeloid Leukemia
100%
Pleura Effusion
33%
Diseases
16%
Side Effect
16%
Protein Tyrosine Kinase Inhibitor
16%
Overall Survival
16%
Survival Rate
16%
Bone Marrow Suppression
16%
Abelson Kinase
16%
Event Free Survival
16%